Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR

被引：1
|
作者：
Floch, Nicolas [1 ]
Bickerton, Sue [1 ]
Martin, Matthew J. [1 ]
Cross, Darren A. [1 ]
Smith, Paul D. [1 ]
机构：
[1] AstraZeneca, Cambridge, England
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-1330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1330
引用
收藏
页数：2
相关论文
共 9 条
  • [1] Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
    Floc'h, Nicolas
    Lim, Sangbin
    Bickerton, Sue
    Ahmed, Afshan
    Orme, Jonathan
    Urosevic, Jelena
    Martin, Matthew J.
    Cross, Darren A. E.
    Cho, Byoung Chul
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2298 - 2307
  • [2] Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
    Floc'h, Nicolas
    Ashton, Susan
    Bianco, Ambra
    Colclough, Nicola
    Cross, Darren A. E.
    Cuomo, Maria Emanuela
    Finlay, M. Raymond V.
    Martin, Matthew J.
    Menard, Ludovic
    McKerrecher, Darren
    O'Neill, Daniel J.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Ward, Richard A.
    Yates, James W. T.
    CANCER RESEARCH, 2017, 77
  • [3] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
    Floc'h, Nicolas
    Martin, Matthew J.
    Riess, Jonathan W.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Menard, Ludovic
    Cuomo, Maria Emanuela
    O'Neill, Daniel J.
    Ward, Richard A.
    Finlay, M. Raymond V.
    McKerrecher, Darren
    Cheng, Mingshan
    Vang, Daniel P.
    Burich, Rebekah A.
    Keck, James G.
    Gandara, David R.
    Mack, Philip C.
    Cross, Darren A. E.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 885 - 896
  • [4] Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo
    Li, Jing
    Li, Yan
    Feng, Zhi-qiang
    Chen, Xiao-guang
    CANCER LETTERS, 2009, 279 (02) : 213 - 220
  • [5] Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
    Silvia La Monica
    Roberta Minari
    Daniele Cretella
    Lisa Flammini
    Claudia Fumarola
    Mara Bonelli
    Andrea Cavazzoni
    Graziana Digiacomo
    Maricla Galetti
    Denise Madeddu
    Angela Falco
    Costanza Annamaria Lagrasta
    Anna Squadrilli
    Elisabetta Barocelli
    Alessandro Romanel
    Federico Quaini
    Pier Giorgio Petronini
    Marcello Tiseo
    Roberta Alfieri
    Journal of Experimental & Clinical Cancer Research, 38
  • [6] Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
    La Monica, Silvia
    Minari, Roberta
    Cretella, Daniele
    Flammini, Lisa
    Fumarola, Claudia
    Bonelli, Mara
    Cavazzoni, Andrea
    Digiacomo, Graziana
    Galetti, Maricla
    Madeddu, Denise
    Falco, Angela
    Lagrasta, Costanza Annamaria
    Squadrilli, Anna
    Barocelli, Elisabetta
    Romanel, Alessandro
    Quaini, Federico
    Petronini, Pier Giorgio
    Tiseo, Marcello
    Alfieri, Roberta
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [7] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
  • [8] Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models
    Lucas, M.
    Merchant, M.
    O'Connor, M.
    Smith, S.
    Trombino, A.
    Waters, N.
    Eathiraj, S.
    Ball, J.
    Breschi, A.
    Igartua, K.
    Kang, M.
    Buck, E.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S23 - S23
  • [9] BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC).
    Lim, Sun Min
    Park, Chae Won
    Zhang, Zhuo
    Woessner, Rich
    Dineen, Tom
    Stevison, Faith
    Hsieh, John
    Eno, Meredith
    Wilson, Doug
    Campbell, John
    Utt, Caitlin
    Albayya, Faris
    Lamontagne, Nicolas
    Dorsch, Marion
    Hoeflich, Klaus
    Cho, Byoung Chul
    Schalm, Stefanie
    CANCER RESEARCH, 2021, 81 (13)
1